Suppr超能文献

使用内切酶和质粒安全 ATP 依赖型 DNA 酶以及选择性引物的实时 PCR 检测乙型肝炎病毒 cccDNA 的方法,特异性得到增强。

Enhanced specificity of real-time PCR for measurement of hepatitis B virus cccDNA using restriction endonuclease and plasmid-safe ATP-dependent DNase and selective primers.

机构信息

Key Laboratory of Artificial Cell, Institute for Hepatobiliary Disease, Tianjin Third Central Hospital, Tianjin, China.

出版信息

J Virol Methods. 2010 Oct;169(1):181-7. doi: 10.1016/j.jviromet.2010.07.031. Epub 2010 Aug 5.

Abstract

The persistence of covalently closed circular DNA (cccDNA) of hepatitis B virus (HBV) in hepatocytes plays a key role in viral persistence and resistance to therapy. Therefore, quantitative cccDNA measurement is of clinical importance for evaluating the efficacy of antiviral drugs, selecting an appropriate treatment strategy, and predicting the prognosis. Current established methods for measurement of cccDNA need further improvement. A modified method was developed using digestion with restriction endonucleases that do not recognize sites in the HBV DNA and plasmid-safe ATP-dependent DNase (PSAD), and using a cccDNA-specific primer set in a real-time PCR reaction. The cccDNA-specific primer has a similar amplification efficiency as a commercial kit. Treatment of samples with restriction endonuclease followed by PSAD digestion increased significantly the specificity of a cccDNA-selective primer set compared with other treatments (P<0.05). Analysis of 35 serum and liver DNA samples from patients with hepatocellular carcinoma demonstrated that the amount of serum cccDNA is beyond the minimum detection limit and that the liver cccDNA quantity is about 0-49.2 copies/cell, consistent with previous reports. Taken together, this method has the potential for evaluating the efficacy of antiviral drugs.

摘要

乙型肝炎病毒 (HBV) 共价闭合环状 DNA (cccDNA) 在肝细胞中的持续存在在病毒持续存在和对治疗的耐药性方面起着关键作用。因此,定量 cccDNA 测量对于评估抗病毒药物的疗效、选择适当的治疗策略和预测预后具有重要的临床意义。目前用于测量 cccDNA 的既定方法需要进一步改进。使用不识别 HBV DNA 位点的限制性内切酶和质粒安全 ATP 依赖性 DNase (PSAD) 进行消化,并在实时 PCR 反应中使用 cccDNA 特异性引物集,开发了一种改良的方法。cccDNA 特异性引物的扩增效率与商业试剂盒相似。与其他处理方法相比,用限制性内切酶处理样品,然后用 PSAD 消化,大大提高了 cccDNA 选择性引物集的特异性(P<0.05)。对来自肝细胞癌患者的 35 份血清和肝 DNA 样本的分析表明,血清 cccDNA 的量超过了最低检测限,肝 cccDNA 的量约为 0-49.2 拷贝/细胞,与之前的报告一致。总之,该方法具有评估抗病毒药物疗效的潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验